Sandoz Issues Class 4 Medicines Defect Notification for Apixaban Tablets
Sandoz Ltd. reported that the Patient Information Leaflet for certain batches of Apixaban tablets lacks up-to-date information.
Asset / Drug
Drug and asset intelligence for Apixaban with 2 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.